| Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development M Ovacik, K Lin Clinical and translational science 11 (6), 540-552, 2018 | 216 | 2018 |
| Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody K Staflin, CLZ de Zafra, LK Schutt, V Clark, F Zhong, M Hristopoulos, ... JCI insight 5 (7), 2020 | 72 | 2020 |
| Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells M Dillon, Y Yin, J Zhou, L McCarty, D Ellerman, D Slaga, TT Junttila, ... MAbs 9 (2), 213-230, 2017 | 66 | 2017 |
| Use of genomic data in risk assessment case study: II. Evaluation of the dibutyl phthalate toxicogenomic data set SY Euling, LD White, AS Kim, B Sen, VS Wilson, C Keshava, N Keshava, ... Toxicology and applied pharmacology 271 (3), 349-362, 2013 | 52 | 2013 |
| Circadian signatures in rat liver: from gene expression to pathways MA Ovacik, S Sukumaran, RR Almon, DC DuBois, WJ Jusko, ... BMC bioinformatics 11, 1-15, 2010 | 32 | 2010 |
| Logic-based and cellular pharmacodynamic modeling of bortezomib responses in U266 human myeloma cells VL Chudasama, MA Ovacik, DR Abernethy, DE Mager Journal of Pharmacology and Experimental Therapeutics 354 (3), 448-458, 2015 | 31 | 2015 |
| A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma S Kakiuchi-Kiyota, T Ross, HA Wallweber, JR Kiefer, MM Schutten, ... Leukemia 36 (4), 1006-1014, 2022 | 22 | 2022 |
| Transcriptional and metabolic flux profiling of triadimefon effects on cultured hepatocytes VV Iyer, MA Ovacik, IP Androulakis, CM Roth, MG Ierapetritou Toxicology and applied pharmacology 248 (3), 165-177, 2010 | 22 | 2010 |
| Pathway modeling of microarray data: a case study of pathway activity changes in the testis following in utero exposure to dibutyl phthalate (DBP) MA Ovacik, B Sen, SY Euling, KW Gaido, MG Ierapetritou, IP Androulakis Toxicology and applied pharmacology 271 (3), 386-394, 2013 | 17 | 2013 |
| Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties AM Ovacik, J Li, M Lemper, D Danilenko, N Stagg, M Mathieu, D Ellerman, ... MAbs 11 (2), 422-433, 2019 | 16 | 2019 |
| On the potential for integrating gene expression and metabolic flux data MA Ovacik, IP Androulakis Current Bioinformatics 3 (3), 142-148, 2008 | 14 | 2008 |
| Anti-LYPD1/CD3 T-cell-dependent bispecific antibody for the treatment of ovarian cancer AA Lo, J Johnston, J Li, D Mandikian, M Hristopoulos, R Clark, D Nickles, ... Molecular Cancer Therapeutics 20 (4), 716-725, 2021 | 10 | 2021 |
| Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma S Kakiuchi-Kiyota, MM Schutten, AO Adedeji, H Cai, R Hendricks, L Liu, ... Cancer Res 80 (16Supplement), 4556, 2020 | 9 | 2020 |
| Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity S Ait-Oudhia, MA Ovacik, DE Mager MAbs 9 (1), 15-28, 2017 | 9 | 2017 |
| Enzyme sequence similarity improves the reaction alignment method for cross-species pathway comparison MA Ovacik, IP Androulakis Toxicology and applied pharmacology 271 (3), 363-371, 2013 | 9 | 2013 |
| Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, a novel anti-BCMA/CD16A bispecific tetravalent antibody for the treatment of multiple myeloma H Cai, S Kakiuchi-Kiyota, R Hendricks, S Zhong, L Liu, AO Adedeji, ... The AAPS Journal 24 (6), 100, 2022 | 7 | 2022 |
| Novel anti-LY6G6D/CD3 T-cell–dependent bispecific antibody for the treatment of colorectal cancer P Wang, LL Sun, R Clark, M Hristopoulos, CPC Chiu, M Dillon, WY Lin, ... Molecular Cancer Therapeutics 21 (6), 974-985, 2022 | 6 | 2022 |
| Nonclinical pharmacokinetics and pharmacodynamics characterization of anti-CD79B/CD3 T cell-dependent bispecific antibody using a surrogate molecule: a potential therapeutic … R Yadav, S Sukumaran, TS Zabka, J Li, A Oldendorp, G Morrow, A Reyes, ... Pharmaceutics 14 (5), 970, 2022 | 5 | 2022 |
| Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic … R Yadav, S Sukumaran, J Lutman, MS Mitra, W Halpern, T Sun, ... Journal of Pharmaceutical Sciences 112 (11), 2910-2920, 2023 | 3 | 2023 |
| An approach to using genomic data in risk assessment: Dibutyl phthalate (DBP) case study SY Euling, L White, M Ovacik, S Makris, B Sen, IP Androulakis, S Hester, ... Reproductive Toxicology 28 (2), 119, 2009 | 3 | 2009 |
Ioannis (Yannis) P. AndroulakisRutgers, The State University of New JerseyEmail verificata su soe.rutgers.edu
